CL2E-SN38 (TFA)

• Description:

  CL2E-SN-38 TFA, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC) . SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor[1].

• UNSPSC:

  12352203

• Target:

  Drug-Linker Conjugates for ADC

• Type:

  ADC Related

• Related Pathways:

  Antibody-drug Conjugate/ADC Related

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/cl2e-sn38-tfa.html

• Purity:

  99.51

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  O=C1N(C2)C(C(C2=C(C3=C4)CC)=NC3=CC=C4OC(N(C)CCN(C)C(OCC(C=C5)=CC=C5NC([C@H](CCCCN)NC([C@@H](NC(COCC(NCCOCCOCCOCCOCCOCCOCCOCCOCCN(N=N6)C=C6CNC(C(CC7)CCC7CN(C8=O)C(C=C8)=O)=O)=O)=O)CC9=CC=CC=C9)=O)=O)=O)=O)=CC([C@](O)%10CC)=C1COC%10=O.O=C(O)C(F)(F)F

• Molecular Formula:

  C89H117F3N14O26

• Molecular Weight:

  1855.95

• References & Citations:

  [1]Lianqi Liu, et al. Synthesis and evaluation of highly releasable and structurally stable antibody-SN-38-conjugates. Drug Deliv. 2021 Dec;28 (1) :2603-2617.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light, stored under nitrogen)

• Scientific Category:

  ADC Related

• Clinical Information:

  No Development Reported